ClinicalTrials.gg
CompletedNCT04073849Updated Mar 17, 2021

CD71 in Dried Blood Spots in Healthy Males

An Early Phase 1 interventional study of EPOGEN® (epoetin alfa) and Normal Saline in Healthy Athletes, sponsored by Sports Medicine Research and Testing Laboratory. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-17.

Sponsored by Sports Medicine Research and Testing Laboratory · Early Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2020, 6 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Understand the effect of recombinant EPO (rEPO) boosting and microdosing on the hematological module of the Athlete Biological Passport (ABP)

  • Measure the change in CD71 longitudinally in subjects from both cohorts
  • Assess whether rEPO administration can be detected in a dried blood spot (DBS) using recent advances in analytical methodologies
  • Compare windows of rEPO detection using both Athlete Biological Passport models and direct detection using analytical methods in urine, blood, and DBS
Read the detailed description

Despite being banned by the World Anti-Doping Agency, blood doping is a common method of performance enhancement used by athletes wishing to gain an unfair advantage over their competition. A common way to achieve this increase is by using erythropoiesis stimulating agents (ESA's), namely recombinant erythropoietin (rEPO). Though laboratory tests have been developed for the direct detection of all known isoforms of exogenously administered ESAs in both urine and blood, athletes have found ways to circumvent these testing measures using techniques such as microdosing.

02

Conditions studied

  • Healthy Athletes
03

In context

Lead sponsor

Sports Medicine Research and Testing Laboratory is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Active individuals, preferably those that participate regularly in endurance athletics either for sport or for leisure, between the ages of 18 and 45

  • Participants should have ferritin > 35 ng/mL and transferrin saturation > 20% at the time of enrollment

Exclusion Criteria: Individuals currently enrolled in a registered testing pool for anti-doping purposes

  • Individuals with the intent to compete in sanctioned athletic events during the study period
  • Unwillingness to provide urine samples or blood samples
  • Not actively exercising
  • Individuals who show a high risk for MI/CAD, stroke, CHF, and venous thromboembolism (VTE)., as defined by the Principal Investigator
  • Individuals with known drug allergies
  • Individuals with abnormalities, as determined by the Principal Investigator
  • Individuals who have chronic kidney disease, , cancer, , , or are planning surgery during the study
  • Individuals with history of acute or chronic medical or psychiatric condition
  • () \<60 mL/min
  • Ferritin >270 ng/mL
  • Individuals who have a baseline concentration greater than 15.5 g/dL or a baseline hematocrit above 47%
  • Individuals with blood or iron disorders, including polycythemia, hemochromatosis, anemia, or iron-deficiency anemia
  • Individuals with a history of bleeding or bone marrow aplasia
  • Individuals who are diabetic or with a history of cardiac or hepatic disease or history of drug abuse
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Cohort A

    EPOGEN® (epoetin alfa) Study Drug Epoetin Alfa (EPOGEN®) 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections

    Drug: EPOGEN® (epoetin alfa)

  • Sham comparator
    Cohort B

    Saline 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections

    Other: Normal Saline

Interventions

  • Active drug

    Also known as: erythropoietin, rEPO

  • OtherNormal Saline

    Placebo

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. CD71 (transferrin receptor) concentration

    CD71 concentration will be measured during and following administration and will be compared to established baseline values from each individual and the study population to understand the changes caused by this dosing pattern of rEPO. These data, especially when comparing to the variability in CD71 in the placebo cohort, may be extrapolated in the anti-doping framework to detect rEPO abuse by athletes.

    Time frame: 8 months

  2. Hemogloblin concentration

    Hemoglobin concentration will be measured during and following administration and will be compared to established baseline values from each individual and the study population to understand the changes caused by this dosing pattern of rEPO

    Time frame: 8 months

  3. Reticulocyte percentage (Ret%)

    Ret% will be measured during and following administration and will be compared to established baseline values from each individual and the study population to understand the changes caused by this dosing pattern of rEPO

    Time frame: 8 months

  4. Calculated OFF-score

    Calculated using the formula: OFF-score = Hgb - 60\*√Ret%, OFF-score will be calculated from each collection during and following administration and will be compared to established baseline values from each individual and the study population to understand the changes caused by this dosing pattern of rEPO

    Time frame: 8 months

  5. Immature reticuocyte fraction

    The immature reticulocyte fraction (IRF) will be measured during and following administration and will be compared to established baseline values from each individual and the study population to understand the changes caused by this dosing pattern of rEPO.

    Time frame: 8 months

Secondary outcomes

  1. Window of detection (detectability time) following rEPO use

    The length of time (following both the subcutaneous 'boosting' phase and the intravenous 'microdosing' phase) that rEPO use is evident will be assessed. This will be assessed using different criteria: 1. Direct detection of the rEPO drug in urine, serum (and/or plasma), and dried blood spots 2. b. Athlete Biological Passport adaptive model

    Time frame: 12 months

  2. Analytical detection of rEPO in a dried blood spot

    Dried blood spot samples will be extracted and analyzed using analytical techniques (namely SAR-PAGE, SDS-PAGE, IEF-PAGE, or others) employed by the laboratory for the direct detection of rEPO.

    Time frame: 12 months

07

Study locations

1 site
  • Sports Medicine Research and Testing Laboratory
    Salt Lake City, Utah 84108, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Nov 2020, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2019
First posted
Aug 29, 2019
StartActual
Jul 15, 2019
Primary completionActual
Nov 15, 2020
CompletionActual
Dec 1, 2020
Last update
Mar 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04073849
Lead sponsor
Sports Medicine Research and Testing Laboratory
Responsible party
Sponsor
First posted
Aug 29, 2019
Start date
Jul 15, 2019
Primary completion
Nov 15, 2020
Completion
Dec 1, 2020
Last update
Mar 17, 2021

Study contacts

Daniel Eichner, PhD
study director · Sports Medicine Research and Testing Laboratory
Andre Crouch, MD
principal investigator · Sports Medicine Research and Testing Laboratory

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion